Leinco Technologies

Anti-Human CD13 - PE

Product Code:
 
LEI-C152
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
22A5
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Flow Cytometry
Shipping:
 
2-8°C
Storage:
 
This R-PE conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C152-50ug50 ug£170.00
Quantity:
LEI-C152-100ug100 ug£232.00
Quantity:
LEI-C152-200ug200 ug£333.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
The CD13 antigen is present on most cells of myeloid origin, including granulocytes and monocytes in normal peripheral blood. CD13 is not expressed on B-cells, T-cells, platelets or erythrocytes. Expression of this antigen is greater on monocytes than on granulocytes.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
R-phycoerythrin (PE)
Format:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Long Description:
Anti-Human CD13 can be used to study myeloid cell functions as well as to immunophenotype leukemias. CD13 is present on basophils from subjects with chronic myeloid leukemia (CML) and on granulocytes from subjects with systemic lupus erythematosus (SLE).
NCBI Gene:
290
Target:
CD13

References

1. Horton, A. M. et al. (1985) Cancer Res. 45:5663 Phycobilliproteins are protected under the following patents: (U.S. patents No. 4,520,110 and 4,542,104, European patent no. 76695, Canadian patent No. 1,179,942 and Australian patent No. 548,440).